Fused heterocyclic compounds as selective BMP inhibitors
US-10196392-B2 · Feb 5, 2019 · US
Inhibition of BMP signaling, compounds, compositions and uses thereof
US10745400B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10745400-B2 |
| Application number | US-201916353745-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 14, 2019 |
| Priority date | Mar 14, 2018 |
| Publication date | Aug 18, 2020 |
| Grant date | Aug 18, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted imidazo[1,2-a]pyridines.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound having a structure of Formula I or a pharmaceutically acceptable salt thereof: wherein R 1 and R 2 are each independently H or halo; A is X 1 is O or NH; X 2 is CR 4 R 5 or —CH 2 CH 2 —; X 3 is CR 8 R 9 or NH; R 3 , R 4 , and R 5 are each independently H or alkyl, or R 4 and R 5 combine to form an optionally substituted 4-, 5-, or 6-membered ring; R 6 and R 7 combine to form an optionally substituted 4-, 5-, or 6-membered ring; and R 8 and R 9 are each independently H or alkyl, or R 8 and R 9 combine to form an optionally substituted 4-, 5-, or 6-membered ring. 2. The compound of claim 1 , wherein R 1 is F and R 2 is F. 3. The compound of claim 1 , wherein X 1 is O. 4. The compound of claim 1 , wherein X 1 is NH. 5. The compound of claim 1 , wherein R 4 and R 5 combine to form an optionally substituted 5 or 6-membered ring. 6. The compound of claim 1 , wherein X 3 is NH. 7. The compound of claim 1 , wherein R 6 and R 7 combine to form an optionally substituted 4- or 5-membered ring. 8. The compound of claim 1 , wherein R 8 and R 9 combine to form an optionally substituted 4-, 5- or 6-membered ring. 9. The compound of claim 1 , wherein A is 10. A compound having the structure of Formula II or a pharmaceutically acceptable salt thereof: wherein G is and J is selected from optionally substituted heteroaryl or 11. The compound of claim 10 , wherein G is 12. The compound of claim 10 , wherein J is 13. The compound of claim 10 , wherein J is 14. A compound selected from: or a pharmaceutically acceptable salt thereof. 15. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 16. A pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable carrier. 17. A pharmaceutical composition comprising a compound of claim 14 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
- C07D471/04Primary
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10745400B2 cover?
- Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted imidazo[1,2-a]pyridines.
- Who is the assignee on this patent?
- Univ Vanderbilt, Vanderbuilt Univ, La Jolla Pharmaceuticals Company
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).